AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$OMER

HANISH ARNOLD C sold $282K of OMER

HANISH ARNOLD C sold 15,000 shares of OMEROS CORP (OMER) at an average of $18.81 ($18.53–$19.02, $0.28M total) across 3 trades over 2026-08-26 to 2026-08-27.

Original reporting
SEC EDGAR · HANISH ARNOLD C
Published Aug 28, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OMER
Bearish
medium confidence
Mentioned
$OMER
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERBearishLow
01

Why it matters

The filing provides fresh data on insider holdings, offering a modest trading signal.

02

Market read

New insider sale information with limited material impact.

03

What to watch

No other insider activity reported; the market may have already priced in typical director sales.

Relevance 4/10Novelty 5/10Timing: today

Background

Form 4 filing discloses insider transactions; director exits are noteworthy but often low‑impact.

Company-level read

Ticker impact

$OMERBearishMedium confidence
Context

Director Hanish Arnold C sold 15,000 shares for $282,094, reducing his stake to zero.

Expected impact

Modest short‑term downside pressure, likely 1‑2% dip.

Evidence & confidence

The sale size is modest but represents a complete exit by a board member, which can be interpreted as a negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

Limited to U.S. markets where OMER trades.

Global

Low

Counterpoint

What could challenge this read

The sale could be unrelated personal liquidity need, not a confidence issue.

Key entities

  • Company
    OMEROS Corp

    Biotech company listed on NASDAQ under ticker OMER.

  • Individual
    Hanish Arnold C

    Director of OMEROS Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OMER insider trading history →

Related articles

OCT 19
$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

european-biotechnology.com3 min
OCT 16
$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.

investing.com2 min